Warning: The NCBI web site requires JavaScript to function. more...
Breast cancer subtypes and survival in patients with brain metastases.
Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J.
Breast Cancer Res. 2008;10(1):R20. Epub 2008 Feb 28.
Related citations
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V.
Breast. 2006 Apr;15(2):219-25. Epub 2005 Jul 18.
Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.
Tumori. 2010 Jan-Feb;96(1):103-10.
Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA, Bauer KR, Brown MM, Caggiano V.
Breast J. 2009 Nov-Dec;15(6):593-602. Epub 2009 Sep 17.
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.
Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS.
J Neurooncol. 2008 Jul;88(3):359-65. Epub 2008 Apr 9.
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
Clin Cancer Res. 2007 Apr 15;13(8):2329-34.
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
Cancer. 2008 Mar 1;112(5):995-1000.
Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, Blair P, Price CG.
Am J Clin Oncol. 2008 Jun;31(3):250-4.
The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V.
Cancer. 2008 Feb 15;112(4):737-47.
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.
J Clin Oncol. 2008 Mar 20;26(9):1419-26. Epub 2008 Feb 19.
Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G, Lee SS, Ahn JH, Jung KH, Lee H, Gong G, Kim HH, Ahn SD, Son BH, Ahn SH, Kim SB.
Breast Cancer Res Treat. 2011 Jul;128(1):171-7. Epub 2011 Apr 26.
Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.
Arch Gynecol Obstet. 2009 Jul;280(1):43-8. Epub 2008 Dec 11.
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A.
Eur J Cancer. 2009 Nov;45(16):2792-8. Epub 2009 Jul 28.
Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.
Oncol Rep. 2010 May;23(5):1213-20.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.
JAMA. 2006 Jun 7;295(21):2492-502.
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A.
J Clin Oncol. 2009 Aug 20;27(24):3908-15. Epub 2009 Jul 20.
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C.
J Clin Oncol. 2009 Mar 10;27(8):1168-76. Epub 2009 Feb 9.
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K, Parise C, Caggiano V.
BMC Cancer. 2010 May 21;10:228.
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.
Breast Cancer Res Treat. 2009 Jan;113(2):357-70. Epub 2008 Mar 7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on